Clinical Trial Update: Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating camrelizumab in combination with chemotherapy or apatinib mesylate as first-line therapy for recurrent or metastatic head and neck sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED